CIT-Logo-White Created with Sketch.

MENU
Device Guides
Trial Guide
Centers
Coding CTO DES Hypertension Imaging Modalities PCI Pharmacology Radial Regulatory Structural Disease Valvular Interventions
News Current Issue Archive Device Guide Calendar Subscribe Advertising About Contact Privacy Submissions

Advertisement

Search Results

Refine by Content Type

close Created with Sketch.

Refine by Year

close Created with Sketch.

Sort By:

Relevance Date

Choose Sites to Search:

CIToday CIToday + EVToday

cit | Article | March/April 2024

Balloon Pulmonary Angioplasty in CTEPH and CTEPD: Where Is This All Going?

BPA is a promising therapeutic option for inoperable CTEPH, a highly disabling consequence of PE; however, randomized controlled trials are needed to assess its ultimate benefits.

By Riyaz Bashir, MD, FACC, RVT; William R. Auger, MD, FCCP; and Kenneth Rosenfield, MD, MHCDS

cit | Article | March/April 2025

Ask The Experts: How Does PE Clot Location/Distribution Affect Your Therapy Decision-Making?

Reflections on how device selection and therapeutic approach for pulmonary embolism are impacted by factors such as thrombus location, clot burden, and patient risk profile.

With Taisei Kobayashi, MD; Riyaz Bashir, MD, FACC, RVT; and Kenneth Rosenfield, MD, MHCDS

cit | News | January 22, 2024

Thrombolex RESCUE II Study Begins Patient Enrollment

January 22, 2024—Thrombolex, Inc. announced the enrollment of the first patient in the RESCUE II study using the company’s Bashir endovascular catheter for the treatment of acute intermediate-risk pulmonary embolism (PE).

cit | News | October 24, 2023

Thrombolex Bashir Catheter Analyzed for Acute Intermediate-Risk PE Patients in RESCUE

October 24, 2023—Thrombolex, Inc., a Pennsylvania-based medical device company focused on the treatment of arterial and venous thromboembolic diseases, announced the publication of an independent core-lab data analysis of 107 patients with acute intermediate-risk pulmonary embolism (PE) treated with the company’s Bashir endovascular catheter and small doses of recombinant tissue plasminogen activator (r-tPA) at 18 sites in the United States.

Advertisement

cit | Article | March/April 2025

Emerging Options for Aortic Regurgitation

By Matti Adam, MD, and Jonathan Curio, MD

cit | News | July 28, 2019

Thrombolex Begins Early Feasibility and Safety Study of the Bashir Catheter for PE

July 29, 2019—Thrombolex, Inc. announced the enrollment of the first patient in the early feasibility and safety study investigating the company's Bashir endovascular catheter for the treatment of submassive pulmonary embolism (PE).

cit | Article | March/April 2024

TAVR Update

By Vivian G. Ng, MD

Advertisement

Endovascular Today
CIT-Logo-Color Created with Sketch.
bmc-secondary-mark-color copy Created with Sketch.

© 2026 Bryn Mawr Communications II, LLC.  
All Rights Reserved   •   Privacy Policy

one-trust-button